NVS—FDA Panel Rejects High-Dose QAB149 by 12-5 Vote
[The advisory panel endorsed the low (75mcg) dose of QAB149 by a 13-4 vote; however, the high (150mcg) dose of QAB149 is highly consequential to NVS’ commercial prospects because it’s the dose NVS is testing in a combination drug for COPD known as QVA149 (#msg-60523825). QVA149 consists of QAB149 (f/k/a Indacaterol, Onbrez Breezhaler), a LABA, and NVA237, a LAMA. The advisory panel’s rejection of the high dose of QAB149 as monotherapy suggests that QVA149 will have some headwinds to overcome in its own review even if the QVA149 phase-3 trials are successful.
SILVER SPRING, Md., March 8 (Reuters) - The higher dose of a proposed Novartis (NVS) lung drug should not be approved, U.S. government advisers said on Tuesday in a 12-5 vote.
The Food and Drug Administration advisory panel voted 13-4 to recommend approval of the lower, 75-microgram dose of the inhaled drug, indacaterol, for treating chronic obstructive pulmonary disease.
Industry analysts say the higher dose is key because Novartis is testing it as part of a two-in-one medicine the company is studying that could bring blockbuster sales.
The FDA usually follows panel recommendations. A final decision is due by April 1.‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.